Jennifer K. Simpson - Net Worth and Insider Trading

Jennifer K. Simpson Net Worth

The estimated net worth of Jennifer K. Simpson is at least $125 dollars as of 2024-11-07. Jennifer K. Simpson is the President & CEO of Delcath Systems Inc and owns about 11 shares of Delcath Systems Inc (DCTH) stock worth over $120. Jennifer K. Simpson is also the President and CEO of Panbela Therapeutics Inc and owns about 13 shares of Panbela Therapeutics Inc (PBLA) stock worth over $5. Details can be seen in Jennifer K. Simpson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jennifer K. Simpson has not made any transactions after 2023-01-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jennifer K. Simpson

Jennifer K. Simpson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jennifer K. Simpson owns 4 companies in total, including Panbela Therapeutics Inc (PBLA) , Delcath Systems Inc (DCTH) , and Eagle Pharmaceuticals Inc (EGRX) among others .

Click here to see the complete history of Jennifer K. Simpson’s form 4 insider trades.

Insider Ownership Summary of Jennifer K. Simpson

Ticker	Comapny	Transaction Date	Type of Owner
PBLA	Panbela Therapeutics Inc	2023-01-30	director & President and CEO
DCTH	Delcath Systems Inc	2018-09-28	President & CEO
EGRX	Eagle Pharmaceuticals Inc	2019-08-28	director
		2021-07-29	director

Jennifer K. Simpson Latest Holdings Summary

Jennifer K. Simpson currently owns a total of 2 stocks. Among these stocks, Jennifer K. Simpson owns 11 shares of Delcath Systems Inc (DCTH) as of September 28, 2018, with a value of $120 and a weighting of 96.36%. Jennifer K. Simpson also owns 13 shares of Panbela Therapeutics Inc (PBLA) as of January 30, 2023, with a value of $5 and a weighting of 3.64%.

Latest Holdings of Jennifer K. Simpson

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DCTH	Delcath Systems Inc	2018-09-28	11	10.94	120
PBLA	Panbela Therapeutics Inc	2023-01-30	13	0.35	5

Holding Weightings of Jennifer K. Simpson

Jennifer K. Simpson Form 4 Trading Tracker

According to the SEC Form 4 filings, Jennifer K. Simpson has made a total of 0 transactions in Delcath Systems Inc (DCTH) over the past 5 years. The most-recent trade in Delcath Systems Inc is the acquisition of 11 shares on September 28, 2018, which cost Jennifer K. Simpson around $12,948.

According to the SEC Form 4 filings, Jennifer K. Simpson has made a total of 2 transactions in Panbela Therapeutics Inc (PBLA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Panbela Therapeutics Inc is the acquisition of 7 shares on January 30, 2023, which cost Jennifer K. Simpson around $6,799.

Insider Trading History of Jennifer K. Simpson

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jennifer K. Simpson Trading Performance

GuruFocus tracks the stock performance after each of Jennifer K. Simpson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jennifer K. Simpson is -42.65%. GuruFocus also compares Jennifer K. Simpson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jennifer K. Simpson within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jennifer K. Simpson's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jennifer K. Simpson

Average Return

Average return per transaction

Outperforming Transactions

0 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-30.11
Relative Return to S&P 500(%)	-29.48

Jennifer K. Simpson Ownership Network

Ownership Network List of Jennifer K. Simpson

No Data

Ownership Network Relation of Jennifer K. Simpson

Jennifer K. Simpson Owned Company Details

What does Panbela Therapeutics Inc do?

Who are the key executives at Panbela Therapeutics Inc?

Jennifer K. Simpson is the director & President and CEO of Panbela Therapeutics Inc. Other key executives at Panbela Therapeutics Inc include V.P. of Finance & CFO Susan Horvath , 10 percent owner Ryan Randall Gilbertson , and 10 percent owner Ryan R. Gilbertson 2012 Irrevocable Trust .

Panbela Therapeutics Inc (PBLA) Insider Trades Summary

Over the past 18 months, Jennifer K. Simpson made no insider transaction in Panbela Therapeutics Inc (PBLA). Other recent insider transactions involving Panbela Therapeutics Inc (PBLA) include a net sale of 72,874 shares made by Goldman Sachs Group Inc ,

In summary, during the past 3 months, insiders sold 0 shares of Panbela Therapeutics Inc (PBLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,644 shares of Panbela Therapeutics Inc (PBLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,644 shares.

Panbela Therapeutics Inc (PBLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Panbela Therapeutics Inc Insider Transactions

No Available Data

What does Delcath Systems Inc do?

Who are the key executives at Delcath Systems Inc?

Jennifer K. Simpson is the President & CEO of Delcath Systems Inc. Other key executives at Delcath Systems Inc include See Remarks Vojo Vukovic , director & Chief Executive Officer Gerard J Michel , and See Remarks Sandra Pennell .

Delcath Systems Inc (DCTH) Insider Trades Summary

Over the past 18 months, Jennifer K. Simpson made no insider transaction in Delcath Systems Inc (DCTH). Other recent insider transactions involving Delcath Systems Inc (DCTH) include a net purchase of 100,000 shares made by Vojo Vukovic , a net purchase of 40,000 shares made by David L. Hoffman , and a net purchase of 34,000 shares made by Gerard J Michel .

In summary, during the past 3 months, insiders sold 0 shares of Delcath Systems Inc (DCTH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Delcath Systems Inc (DCTH) were sold and 282,819 shares were bought by its insiders, resulting in a net purchase of 282,819 shares.

Delcath Systems Inc (DCTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Delcath Systems Inc Insider Transactions

No Available Data

What does Eagle Pharmaceuticals Inc do?

Who are the key executives at Eagle Pharmaceuticals Inc?

Jennifer K. Simpson is the director of Eagle Pharmaceuticals Inc. Other key executives at Eagle Pharmaceuticals Inc include director & President and CEO Scott Tarriff , EVP & Chief Commercial Officer Michael Shawn Moran , and Chief Medical Officer Judith Ng-cashin .

Eagle Pharmaceuticals Inc (EGRX) Insider Trades Summary

Over the past 18 months, Jennifer K. Simpson made no insider transaction in Eagle Pharmaceuticals Inc (EGRX). Other recent insider transactions involving Eagle Pharmaceuticals Inc (EGRX) include a net sale of 101,864 shares made by Scott Tarriff ,

In summary, during the past 3 months, insiders sold 0 shares of Eagle Pharmaceuticals Inc (EGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 101,864 shares of Eagle Pharmaceuticals Inc (EGRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 101,864 shares.

Eagle Pharmaceuticals Inc (EGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eagle Pharmaceuticals Inc Insider Transactions

No Available Data

What does LadRx Corp do?

Who are the key executives at LadRx Corp?

Jennifer K. Simpson is the director of LadRx Corp. Other key executives at LadRx Corp include Chief Executive Officer Stephen Snowdy , Pres. & Chief Operating Officer Eric Curtis , and Vice President Drug Discovery Felix Kratz .

LadRx Corp (LADX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of LadRx Corp (LADX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of LadRx Corp (LADX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

LadRx Corp (LADX)'s detailed insider trading history can be found in Insider Trading Tracker table.

LadRx Corp Insider Transactions

No Available Data

Jennifer K. Simpson Mailing Address

Above is the net worth, insider trading, and ownership report for Jennifer K. Simpson. You might contact Jennifer K. Simpson via mailing address: C/o Delcath Systems, Inc., 810 Seventh Avenue, Suite 3505, New York Ny 10019.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.